tirzepatide en france FDA Grants a New Indication for Obesity Management tirzepatide en france Mounjaro KwikPen

The study enrolled a sufficient proportion of participants who required substantial weight loss84.0% of participants in this global registration trial had a baseline BMI 35 kg/m

GLP-1 and dual GLP-1/GIP agonists may offer superior weight loss

It works by activating two key hormonesGLP-1 and GIP receptorswhich help regulate blood sugar levels, slow digestion, and reduce appetite.

Compared with placebo (7.8%), relative muscle strength (strength normalized to body weight) was higher with exercise (0.4%), liraglutide (+1.0%), and the combined treatment (+3.3%) because of lower weight and preserved absolute strength

This decision raises important questions about safety, access, and the best treatment options for weight management.

Nakawa and our team provide expert, physician-guided weight loss solutions to help you achieve lasting results.